Introduction
Kampo medicine originated in ancient China and developed uniquely in Japan. It has been both taught to, and used by, conventional Western physicians for the last 30 years.
Currently, more than 70% of Japanese physicians (including nearly 100% of Japanese obstetrics and gynaecology (Ob/Gyn) doctors) use Kampo medicine in daily practice including the university hospital, together with high-tech medical treatments like organ transplantation or robotic surgery. Kampo medicine is considered a governmentregulated prescription drug and currently 148 formulas are listed on the Japanese national insurance program.
As for cancer treatment, Kampo medicine is widely used by surgeons and oncologists. It is widely used in the regular practice for the treatment of cancer and cancer-related symptoms from the early stage to the terminal care. Because Kampo medicine has been totally integrated into Western medicine in Japan, motivation to promote clinical trials is lacking. On the contrary, basic research concerning cancer treatment have piled over the last 30 years by the physicians and pharmaceutical researchers. Prevention of recurrence or metastasis of cancer cells have been well studied in basic research, however there is little data in the clinical study because it takes time to accomplish.
In this review article, Kampo treatment for cancer will be described based on the clinical and basic research articles.
[ Special Feature ] levels of AST and ALT, it has been widely used for the treatment of chronic hepatitis. Because chronic hepatitis is very common in Japan as well as other Asian countries and no established treatment is available, Shosaikoto is widely used for the purpose of liver protection. Oka et al.
1 reported on a fi ve-year followup study of liver cirrhosis patients. The subjects were 260 patients and randomly divided into two groups, one treated with Shosaikoto and the other without. Onset of the hepatocellular carcinoma and survival rate were evaluated. The results revealed that the onset of hepatocellular carcinoma decreased and longevity improved in the group with Shosaikoto especially in the group of liver cirrhosis by non-B viruses. In the US, the effectiveness o
f S h o s a i k o t o , H o c h u e k k i t o
and Ninjinyoueito as well as glycirrhizine are listed as the effective treatment for the chronic hepatitis. However the mechanism is not obvious, it is assumed that oxidative stress plays an important role in hepatocarcinogenesis. Shiota et al.
2 investigated the anti-oxidative actions of Shosaikoto, and found that, Shosaikoto inhibited the 8-hydroxy-2'-deoxyguanosine (8-OHDG) formation, which is a DNA adduct by reactive oxygen species and known to be a genetic risk for hepatocarcinogenesis.
Shoseiryuto ( ) for the prevention of lung cancer
In the basic research, there are several reports. One is the Shoseiryuto ( ) for the prevention of lung cancer. Lung cancer was induced in the mouse model by 4-nitroquinolone-N-oxide (4NQO) s.c followed by the glycerol intake. This treatment induced the lung tumor in 93.3% of mice without Shoseiryuto, and 33.3% with Shoseiryuto. This data showed the reduction of the onset of lung cancer with Shoseiryuto.
Shosaikoto ( ) for the prevention of melanoma
Another study was done by Kato et al. 3 He established a RETtransgenic mouse line (304/B6) in which stepwise development of a skin melanocytic benign tumor and malignant melanoma can be observed. In this mouse model, he demonstrated that the herbal medicine Shosaikoto has antitumor and anti-metastatic effects on malignant melanoma through regulation of protein expression levels of matrix metalloproteinase (MMP) and its inhibitor. This study was followed by additional evidence showing that Ret protein expression levels of tumors in Shosaikoto-treated mice were higher than those of tumors in untreated mice at benign, malignant, and terminal stages of the tumors. The reduced Ret expression at the terminal stage was partially restored. From this experiment, it was concluded that the antitumor effect of Shosaikoto involves the promoted preparation of Ret protein as a tumor transplantation antigen, which probably overcomes its potentially increased oncogenic activity.
Treatment with Surgical Operation

Daikenchuto ( ) for the prevention of post-surgical ileus
Daikenchuto has been shown to be effective in preventing the postsurgical ileus and widely used to prevent ileus after abdominal surgeries in the fi eld of not only gastrointestinal but also gynecology. Daikenchuto also prevents post-surgical intestinal adhesion by gastroprokinetic and anti-infl ammatory effects. Motilin,
K a m p o m e d i c i n e i s c o n s i d e r e d a government-regulated
prescription drug and currently 148 formulas a r e l i s t e d o n t h e J a p a n e s e n a t i o n a l insurance program.
I n t h e U S , t h e e f f e c t i v e n e s s o f
Shosaikoto, Hochuekkito and Ninjinyoueito as well as glycirrhizine are listed as the effective t r e a t m e n t f o r t h e chronic hepatitis. [ Special Feature ] one of the neuro-peptides which is a powerful inducer of motor activity in the gastrointestine, was elevated in the blood after the administration of Daikenchuto in humans. In addition, Daikenchuto has been shown to induce production of vasoactive intestinal peptide (VIP) and 5-hydroxytryptamine (serotonin) in human plasma. These neuropeptides may play a role to induce the motility of the gastrointestine. Also, Sanshol in Zanthoxylum piperitum binds to the vaniloid receptor and stimulates the peristalsis.
[6]-shogaol is an important component in dried ginger and produces an increase in the gastrointestinal blood fl ow, which is medicated by calcitonine gene-related peptide (CGRP), and explains why Daikenchuto is useful in the treatment of intestinal ischemia-related diseases. This action is observed only when steamed ginger is used and not the dry ginger.
Steam manipulation is observed in converting the Gingerol to Shogaol in the ginger and this Shogaol is important in secreting CGRP leading to the increase of blood fl ow of the gut as a result.
Prolonged paralytic ileus occurring in the hepatectomized p a t i e n t s m a y i n d u c e h y p e rammonemia. Daikenchuto is used to suppress the elevation of serum ammonia in hepatectomized patients. Presumably, Daikenchuto stimulates the peristalsis and does not allow the growth of the intestinal bacteria producing ammonia. Imazu et al. 4 showed this hypothesis with a different Kampo formula, Juzentaihoto. He showed that the change of the intestinal flora is the main resource of the serum ammonia elevation and this is suppressed by Juzentaihoto, because with Juzentaihoto, the change of the intestinal fl ora was suppressed.
Treatment with Chemotherapy
There are many reports that Kampo treatment reduces the sideeffects of chemotherapy. Juzentaihoto alleviates the side-effect of UFT (Uracil-Tegafur, anti-cancer drug). Six months follow-up study of gastric cancer patients with UFT after curative operation revealed that suppressor T cell function was lower and cytotoxic/killer cell function higher in the group with Juzentaihoto. This study also showed that subjective and objective adverse symptoms caused by UFT were less with Juzentaihoto.
Saireito ( ) alleviates the side-effects of CDDP
Another study examined 26 cases of lung cancer, which was divided into 2 groups, one with Saireito (n = 10) and the other without (n = 16). Nephrotoxicity with cis-diamminedichloroplatinum (CDDP) was evaluated. Serum levels of BUN increased in the group without Saireito, while serum BUN levels were not elevated in the group with Saireito. Also, creatinin clearance became lower and Nacetyl-D-glucosaminidase increased, while those markers stayed as normal in the group with Saireito. This study showed that Saireito is effective in alleviating the nephrotoxicity of CDDP.
Juzentaihoto ( ) alleviates the side-effects of CDDP
Sugiyama et al. 5, 6 screened 11 Kampo formulae to evaluate the protection of nephrotoxicity induced by CDDP. Among the 11 Kampo formulae, nine formulae showed significant reduction of nephrotoxicity. Although Flosemide also reduced the nephrotoxicity, it also diminished the effectiveness of CDDP. Among nine Kampo formulae that reduced the nephrotoxicity, Juzentaihoto was the most effective. Juzentaihoto also protected the liver and suppressed the liver injury. Among the herbs in Juzentaihoto, Angelicae radix showed the most effectiveness in liver and kidney Daikenchuto has been shown to be effective in preventing the posts u r g i c a l i l e u s a n d widely used to prevent ileus after abdominal surgeries in the field of not only gastrointestinal but also gynecology. [ Special Feature ] protection. Sodium malate in Angelicae radix was responsible for protecting the liver and kidney functions. The mechanism of action of sodium malate was that this compound binds to CDDP and forms the diammino-platinum(II) malate, which has a similar chemical structure to the CDDP-derived chemical, Carboplatin (CBDCA). This CBDCA is used clinically and it has less toxicity against the kidney, however, the effect is weaker. Also, this sodium malate did not increase bone toxicity; Juzentaihoto protected the bone marrow and blood cell count was not decreased with Juzentaihoto.
Hangeshashinto ( ) alleviates the side-effects of CPT-11
Another good example that showed the reduction of the side-effects of chemotherapy is Hangeshashinto. Irinotecan hydrochloride (CPT-11), a semisynthetic derivative of camptothecin, is an anti-cancer drug which inhibits nucleic acid synthesis by topoisomerase I inhibition. CPT-11 possesses a wide anti-tumor spectrum and is widely used for the treatment of lung cancer, colon cancer and malignant lymphoma. Diarrhea is the main side-effect that occurs in the early stage and causes the discontinuation of the drug administration. Hangeshashinto is used to stop the irinotecan-induced diarrhea. Mori et al. 7 reported the result of RCT of Hangeshashinto and CPT-11. Of the 41 patients with advanced lung cancer, 18 took Hangeshashinto and 23 did not. Among 41 patients, 39 experienced diarrhea. Although there were no differences of diarrhea frequency and duration, severe diarrhea (grades 3 and 4) was reduced in the group with Hangeshashinto (one among 18 patients) as compared to the group without Hangeshashinto (nine among 23 patients). This study showed that Hangeshashinto is recommended for use with CPT-11. The mechanism of action is also well studied. CPT-11 is changed to 7-ethyl-10 hydroxy-camptotecin (SN-38) in the liver and SN-38 undergoes glucronate conjugation changing into inactive SN-38 glucronide. Later, it is excreted into the bile, and is then deconjugated by β-glucronidase, which was contained in the intestinal bacteria to become SN-38 again. This SN-38 induces delayed diarrhea. Hangeshashinto contains baicalin, which serve as another resource of β-glucronidase. This competitive action of baicalin against SN-38 glucronide inhibited the formation of active form of SN-38 without glucronide. As a result, the delayed diarrhea caused by deconjugated SN-38 was alleviated by Hangeshashinto.
Treatment with Irradiation
There is a report that the irradiation with Kampo improved the survival rate in the progressive uterus cervical cancer. 
Juzentaihoto for the hematopoiesis after irradiation
Effects of Juzentaihoto on the recovery of hemopoietic systems from radiation injury are analyzed. Colony-forming unit-spleen (CFU-S) are hematopoietic colonies formed in the spleen of recipient mice that have been lethally irradiated and injected with donor bone marrow cells. Day-14 CFU-S represents primitive hematopoietic stem cells (HSCs) and day-9 CFU-S represents more mature HSCs. The mice injected with Juzentaihoto-treated bone marrow cells showed better general condition, heavier spleens with larger and more numerous colonies than the control mice on day 14. On the other hand, there was no difference in the number of CFU-S between Juzentaihoto-treated and control groups on day 9. Since the day-14 CFU-S assay is thought to refl ect the most primitive progenitor cells in the hematopoietic system, these results
Among the herbs in
Juzentaihoto, Angelicae radix showed the most effectiveness in liver and kidney protection.
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[ Special Feature ]
strongly suggested that Juzentaihoto acts on stem cells in the G0 phase to manifest recovery-enhancing effects from radiation injury. After this study, the same group fractionated Juzentaihoto to obtain oleic acid and found that linolenic acid in Juzentaihoto was the responsible compound.
Prevention of Recurrence and/or Metastasis
